<DOC>
	<DOCNO>NCT00591292</DOCNO>
	<brief_summary>Dose escalate study orally administer indibulin twice daily schedule subject solid tumor .</brief_summary>
	<brief_title>Phase I Study Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Subjects histological cytological confirmation advance cancer , refractory standard therapy condition 2 . ≥ 18 year age 3 . ECOG performance score ≤ 2 ( see Appendix 3 ) 4 . Eligible subject MUST least one measurable lesion define RECIST guideline ( See Appendix 4 ) . If measurable disease restrict solitary lesion , neoplastic nature confirm cytology/histology . Measurable lesion MUST previously irradiate field injected biological agent . 5 . Lifeexpectancy ≥ 12 week 6 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct &lt; 2 week prior Baseline : Creatinine ≤ 1.5 X upper limit normal ( ULN ) OR calculate creatinine clearance ≥ 50 cc/min Total bilirubin ≤ 1.5 X ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤ 2.5 X ULN White blood cell count ≥3.0 x 109/L Absolute Neutrophil Count ( ANC ) ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥ 10 g/dL 7 . Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee jurisdiction site . Exclusion Criteria 1 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction within 6 month ( see Appendix 5 ) 2 . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation 3 . Pregnant and/or lactate female ( reliable method contraception must use men woman childbearing potential study 3 month last study drug administration ) . 4 . Uncontrolled systemic infection ( documented microbiological study ) 5 . Anticancer chemotherapy immunotherapy study within 4 week study entry . Mitomycin C nitrosureas give within 6 week study entry . 6 . Radiotherapy study within 3 week study entry 7 . Surgery within 4 week start study drug exclude tumor biopsy pharmacodynamic parameter 8 . Investigational drug therapy outside trial within 4 week study entry 9 . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer 10 . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result 11 . Any condition unstable could jeopardize safety subject his/her compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>advanced tumor</keyword>
</DOC>